Smoking-related interstitial fibrosis (SRIF)

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Smoking-related interstitial fibrosis
Synonyms	SRIF
Pronounce	N/A
Specialty	Pulmonology, Pathology
Symptoms	Shortness of breath, cough, fatigue
Complications	Pulmonary hypertension, respiratory failure
Onset	Typically in middle-aged to older adults
Duration	Chronic
Types	N/A
Causes	Cigarette smoking
Risks	Long-term tobacco use
Diagnosis	Lung biopsy, high-resolution computed tomography
Differential diagnosis	Idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease
Prevention	Smoking cessation
Treatment	Smoking cessation, supportive care
Medication	N/A
Prognosis	Variable, depends on extent of fibrosis and smoking cessation
Frequency	Rare, but underrecognized
Deaths	N/A

Smoking-related interstitial fibrosis (SRIF) is a specific type of pulmonary fibrosis that is associated with cigarette smoking. It is characterized by the accumulation of dense collagen fibers in the interstitial spaces of the lung, leading to impaired respiratory function. SRIF is considered a distinct pathological entity within the spectrum of smoking-related lung diseases.

Pathophysiology

The pathogenesis of SRIF involves chronic exposure to the harmful chemicals in cigarette smoke, which leads to repeated injury and inflammation of the lung parenchyma. Over time, this results in the activation of fibroblasts and excessive deposition of collagen in the interstitial spaces. The dense collagen fibers disrupt the normal architecture of the lung, leading to decreased lung compliance and impaired gas exchange.

Clinical Presentation

Patients with SRIF may present with symptoms such as chronic cough, dyspnea (shortness of breath), and reduced exercise tolerance. These symptoms are often insidious in onset and may be mistaken for other smoking-related conditions such as chronic obstructive pulmonary disease (COPD) or emphysema.

Diagnosis

The diagnosis of SRIF is primarily based on histological examination of lung tissue obtained via lung biopsy. The characteristic finding is the presence of dense, eosinophilic collagen bundles in the interstitial spaces, often with minimal associated inflammation. High-resolution computed tomography (HRCT) of the chest may show reticular opacities and interstitial thickening, but these findings are not specific to SRIF.

Treatment

Currently, there is no specific treatment for SRIF. Management focuses on smoking cessation and supportive care to alleviate symptoms. Pulmonary rehabilitation and oxygen therapy may be beneficial for some patients. The progression of fibrosis may stabilize with smoking cessation, but the existing fibrosis is generally irreversible.

Prognosis

The prognosis of SRIF varies depending on the extent of fibrosis and the presence of other smoking-related lung diseases. In general, the condition is slowly progressive, and the degree of functional impairment correlates with the extent of fibrosis. Smoking cessation is crucial in preventing further lung damage.

See Also

• Pulmonary fibrosis
• Chronic obstructive pulmonary disease
• Emphysema
• Lung biopsy